Friday, March 01, 2019 10:00:30 PM
Could this phenomena or problem of using untoward resources of the FDA on large Amyloid Trials be a consequence of the very User Fee Act that to a large part funds the FDA?
Does not the ones who pay the Piper (FDA) get to call the tune? In other words is the dominance of the FDA by BP facilitated by the User Fee Act (PDUFA) since that is what funds the FDA that BP can chase the resources of the FDA down rabbit holes so they do not have the time and resources to divote to promising or even paradigm shifting new drugs of smaller innovative Biopharm Companies and therefore retain their dominant positions in the Drug Industry?
How would Dr Peter Singe analysis the PDUFA dilemma?
Does not in fact the PDUFA by Act of Congress cede effective command and control of the FDA to the deep pockets of the BPs?
It seems all baby Bios can do is clinically try Orphan Drugs where PDUFA fees are waived or discounted.
What the heck is Bill Gates doing? We need real philanthropists like Andrew Carnegie of a prior era that actually use their wealth to make a difference. (System of public libraries which was a huge benefit to the people of the USA)
Down with the Pharmaceutical Drug User Fee Act. It needs to be abolished as it grants a strangle hold on the FDA by BP.
He who pays the Piper calls the tune. Those same Pigs are always at the Tits of Government as long as the money is Green. As in overcharging Fed programs like Medicaid for the drugs.
Long AVXL. Let her torches burn bright so she can show the way to other innovative Biotechs navigating the mine fields sown by BPs and their lap dog the FDA.
Does not the ones who pay the Piper (FDA) get to call the tune? In other words is the dominance of the FDA by BP facilitated by the User Fee Act (PDUFA) since that is what funds the FDA that BP can chase the resources of the FDA down rabbit holes so they do not have the time and resources to divote to promising or even paradigm shifting new drugs of smaller innovative Biopharm Companies and therefore retain their dominant positions in the Drug Industry?
How would Dr Peter Singe analysis the PDUFA dilemma?
Does not in fact the PDUFA by Act of Congress cede effective command and control of the FDA to the deep pockets of the BPs?
It seems all baby Bios can do is clinically try Orphan Drugs where PDUFA fees are waived or discounted.
What the heck is Bill Gates doing? We need real philanthropists like Andrew Carnegie of a prior era that actually use their wealth to make a difference. (System of public libraries which was a huge benefit to the people of the USA)
Down with the Pharmaceutical Drug User Fee Act. It needs to be abolished as it grants a strangle hold on the FDA by BP.
He who pays the Piper calls the tune. Those same Pigs are always at the Tits of Government as long as the money is Green. As in overcharging Fed programs like Medicaid for the drugs.
Long AVXL. Let her torches burn bright so she can show the way to other innovative Biotechs navigating the mine fields sown by BPs and their lap dog the FDA.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
